The ESCP Project is an on-going collaboration between ERN PaedCan and SIOP Europe’s Clinical Trial Groups (ECTG), aiming to develop approved clinical recommendations that reflect current best practices for each common childhood cancer type. The goal is to improve outcomes and increase childhood cancer survival, and quality of life by providing these benchmarks for best practice.

The ESCP Project is collating treatment pathways that reflect current best standards of care, defined by the collective European experts in each field. These expert-endorsed recommendations aim to improve access to best standard treatments for all children with cancer throughout Europe and hold the potential of reducing inequalities in childhood cancer outcomes across Member States. The intended use of these documents is to provide a written recommendation for best standard treatments and can be used as a benchmark where no national recommendations or clinical trial options are available.

The ESCP protocols are available on the SIOP Europe members’ portal (exclusive to SIOP Europe members). Subsequent protocols provide important information to paediatric haemato-oncologists, patients, and families in situations where current standard best clinical practice is either unavailable or front-line trials are not accessible.

For each ESCP, associated surveys are being created which should assess the possibility of implementation of these documents. Two versions of each survey are available: one directed at National Paediatric Haemato-Oncology Societies (NaPHOS) and one targeting CCI-E (the European branch of Childhood Cancer International) member states and ERN PaedCan national contact points from the patient side (i.e. Parents, Survivors, Carers) who should be able to understand the guidance documents in order to be able to support families.

We encourage you to fill out these surveys and help us get a better understanding on how the ESCP documents can be used in your country.

Join the ESCP Webinars to learn more about the project. 

The following ESCP Guidance Documents are accessible through the SIOP Europe Portal:

  • Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents
    • NaPHOS survey: ALL | CCI-E survey: ALL
  • Acute Myeloid Leukemia (AML) in Children and Adolescents
    • NaPHOS survey: AML | CCI-E survey: AML
  • Adrenocortical Tumours in Children and Adolescents
    • NaPHOS survey: ACT | CCI-E survey: ACT
  • Brain Tumour Group – Overview and Discipline Groups
  • Childhood Intracranial Germ Cell Tumours
  • Craniopharyngioma
  • Ewing Sarcoma
  • Familial Leukemia
  • High-Risk Neuroblastoma
  • Low-Risk Neuroblastoma
  • Medulloblastoma
    • NaPHOS survey: MB | CCI-E surveyMB
  • Nasopharyngeal Carcinoma in Children and Adolescents
    • NaPHOS survey: NPC | CCI-E survey: NPC
  • Non-Hodgkin Lymphoma of Childhood and Adolescence
    • NaPHOS survey: NHL | CCI-E survey: NHL
  • Pediatric-Onset Langerhans Cell Histiocytosis
    • NaPHOS survey: LCH | CCI-E survey: LCH
  • Pleuropulmonary Blastoma In Children and Adolescents
    • NaPHOS survey: PPB | CCI-E survey: PPB
  • Rare CNS Embryonal and Sarcomatous Tumours and Astroblastoma, MN1-altered
  • Rhabdomyosarcoma
    • NaPHOS survey: RMS | CCI-E survey: RMS
  • Salivary Gland Carcinoma in Children and Adolescents
    • NaPHOS survey: SGC | CCI-E survey: SGC

This list is updated following every release of a new ESCP document.

We thank the Young SIOPE Members, Clinical Research Council Mentors, the European Clinical Trials Groups Chairs, as well as representatives of the widening countries and Childhood Cancer International Europe Members involved in the project for their invaluable support.

Contact Us

Should you need more information about the ERN PaedCan, please send us an email and we'll get back to you.

Not readable? Change text. captcha txt